Applications

1454 – Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Testing of tumour material in patients with non-small cell lung cancer (NSCLC) to detect chromosomal rearrangements in the ROS1 gene to determine eligibility for treatment with Xalkori (crizotinib) through the PBS.

PBS subsidy will also be sought for Xalkori (crizotinib) for the treatment of patients with ROS1-rearranged NSCLC.

Type: Investigative, co-dependent technology

Medical condition this application addresses

Patients with non-squamous non-small cell lung cancer (NSCLC).

Meetings to consider this application

  • PASC meeting: 8 December 2016
  • ESC meeting: 5 October 2017
  • MSAC meeting: 
    • 23 November 2017
    • 26-27 July 2018